NCT00175864View on ClinicalTrials.gov

Open Label Study (Everyone Who Participates Receives Drug) to Further Determine How Safe and Effective Oral Treatment of Seletracetam is in Patients With Refractory Epilepsy.

PHASE3WithdrawnINTERVENTIONAL
0
Timeline

Start Date

February 28, 2006

Conditions
Epilepsy
Interventions
DRUG

Seletracetam (ucb 44212)

Sponsors

Lead Sponsor

UCB Pharma
All Listed Sponsors
lead

UCB Pharma

INDUSTRY

NCT00175864 - Open Label Study (Everyone Who Participates Receives Drug) to Further Determine How Safe and Effective Oral Treatment of Seletracetam is in Patients With Refractory Epilepsy. | Biotech Hunter | Biotech Hunter